In this episode of Executive Insights for Life Sciences Innovators, we speak with Ben Scruggs, the CEO of Altis Biosciences, a biotechnology company developing advanced human intestinal tissue platforms designed to improve the predictability of drug development.

Ben explains how Altis’ RepliGut® platform addresses long-standing limitations in traditional preclinical gut models, which often fail to replicate human physiology and contribute to costly downstream clinical setbacks. He shares how the company is building scalable, functional human intestinal tissue systems to better model drug absorption, metabolism, toxicity, and inflammatory disease.

We explore the discipline required to commercialize complex biology, the realities of scaling a platform biotechnology company, and how improving translational models can enhance capital efficiency across the pharmaceutical industry. Ben also offers perspective on leadership in deep science ventures, partnering with pharma, and positioning infrastructure technologies for long-term impact.

This episode was streamed live on YouTube on February 23, 2026. Learn more at ⁠⁠⁠⁠⁠genecoda.com⁠⁠⁠⁠⁠.